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Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis presenting with painful and sterile skin 
ulcerations (1). Its aetiology remains largely unknown although an autoinflammatory background seems 
possible. Several comorbidities as well as triggering factors such as surgery, trauma or pharmacological 
therapies have been associated with the development of PG (2). Different topical and systemic treatments are 
recommended for PG, most commonly topical steroids or calcineurin inhibitors as well as systemic steroids, 
dapsone, infliximab and others, as well as by our group and others canakinumab and ustekinumab (3, 4). 
Pyoderma gangrenosum is a diagnosis of exclusion and often misdiagnosed at initial manifestation. 
Hypertensive ischemic leg ulcer Martorell (HYTILU) was previously investigated by our group showing that 50% 
of the patients with a referral diagnosis of PG were found to have HYTILU (5). HYTILU is caused by ischemic 
subcutaneous arteriolosclerosis and all patients showing arterial hypertension and up to 58% diabetes 
mellitus. Typical clinical presentation of HYTILU is a latero-dorsal lower leg ulceration with central black 
necrosis and purple inflamed ulcer borders (5, 6). This appearance can clinically be misleading for PG and 
immunosuppression could be fatal in HYTILU as it strongly increases the risk of septicaemia. (5) In the current 
study we compare our PG with a HYTILU cohort and focus on clinical data, laboratory findings and 
comorbidities to develop diagnostic clues for both diseases.  
 
In the patient files of the Department of Dermatology, University Hospital of Zurich (USZ), Cantonal Hospital of 
Sankt Gallen (KSSG), and in the private practice of Prof. Werner Kempf (USZ) a keyword search for “pyoderma” 
and/or “gangrenosum” was conducted for all patients who were hospitalized between 01.01.2002 and 
31.12.2012. 179 patients were identified with an initial suspected differential diagnosis of PG, of which 38 
patients were diagnosed as PG. We performed a histopathological re-assessment of these 38 patients and 
identified three patients with histopathological signs of HYTILU and one with morphea, leading to exclusion of 
these four patients from further analysis. The remaining 34 patients fulfilled the criteria for PG as established 
by Su et al. and were included in our study (7). These PG patients were retrospectively compared to a cohort of 
32 HYTILU patients diagnosed at the USZ during the same time period. Medical records and laboratory findings 
were analysed for both cohorts in order to identify features which support clinical distinction (Table 1). The 
study was approved by the local ethics committee (KEK-ZH 2014-0432). For statistical analysis GraphPad 
Prism® 7.0b, 2016, and Microsoft Excel® 14.3.2, 2011, were used.  
 
Compared to PG, HYTILU appeared less frequent in women, at later age, more often in smokers, showed 
higher CRP but lower levels of blood leukocytes and neutrophils, lesion localization only at the lower leg, more 
cardiovascular comorbidities such as arterial hypertension, diabetes mellitus, peripheral artery occlusive 
disease, metabolic syndrome and more microbial superinfection (Table 1). 
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Our findings of an elevated CRP and neutrophilia in PG indicates the presence of systemic inflammation, which 
is also increasingly suggested by the field (8). Additionally the reduced likelihood of pathogenic bacteria in PG 
lesions could be explained by the exacerbated neutrophil response. Cardiovascular comorbidities like arterial 
hypertension, peripheral artery occlusive disease, metabolic syndrome and diabetes mellitus appear 
significantly more in HYTILU, which has also been reported previously by our group, as in PG. Upon age-
adjustment the prevalence of cardiovascular comorbidities in our small PG cohort seems to correspond to the 
normal Swiss population, however this needs to be confirmed in bigger studies (5). Furthermore, all of the 
HYTILU patients in our cohort had an ulcer located on the lower leg and as such, a lesion localization outside of 
the lower leg could be a further clinical hint favouring the diagnose of PG (lower leg 67%, trunk 24%, upper 
limb 5%, head 4%). Both cohorts are however rather small and larger cohorts are needed to confirm our 
findings. 
 
Pyoderma gangrenosum and HYTILU are important differential diagnosis for ulcerative skin disorders and 
should be carefully considered. In particular if the biopsy taken in PG and HYTILU is too small, the chance of 
visualizing “PG-like features“ of neutrophilic infiltration and missing the typical features of HYTILU 
(subcutaneous stenotic arteriolosclerosis in 100% and medial calcification in 71% of cases) is high. Our findings 
suggest that differences in lesion localization, laboratory parameters and presence of comorbidities could also 
be utilized in order to accurately differentiate these disorders. We also identified increased inflammatory 
markers in a considerable proportion of our PG patients, which is an expected but not formally proven aspect 
of PG. Larger prospective studies or international registries on these rare ulcerative skin diseases are needed 
to confirm these findings. 
 
Table 1: Comparison HYTILU and PG 
 
  
HYTILU
(n=32) 
PG
(n=34) 
p 
value 
Female gender 50.0% 61.8% ns 
Age at manifestation (years) 73.5 61.2 *** 
BMI (kg/m2) 28.3 24.1 * 
Smoking 25% 20.6% ns 
Alcohol 12.5% 11.8% ns 
Laboratory (mean)       
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CRP (mg/L) 31.5 14.5 ns
Leukocytes (G/L) 9.9 10.5 ns
Neutrophils (G/L) 7.9 8.4 *
Lesion localization lower leg 100% 67% ***
Cardiovascular comorbidities 100% 79.4% **
Arterial hypertension 100% 29.4% ****
PAOD 62.5% 5.9% ****
Hypertensive heart disease 40.6% 11.8% ** 
Myocardial infarction 25.0% 5.9% * 
Other cardiopathy 12.5% 2.9% ns 
Cerebrovascular infarction 21.9% 2.9% * 
Metabolic syndrome 65.6% 2.9% **** 
Diabetes mellitus 53.1% 8.8% **** 
Thrombosis 3.1% 8.8% ns 
Renal insufficiency 28.1% 20.6% ns 
Microbiological swab positive 90.6% 44.1% **** 
 
Table 1: Comparison HYTILU and PG 
Comparison of 32 HYTILU patients (hypertensive ischemic leg ulcer Martorell) and 34 PG patients by 
demographic data, laboratory values, localization, comorbidities.  
PAOD = peripheral artery occlusive disease, BMI = body mass index, CRP = C-reactive protein, kg = Kilogram, m 
= meter, mg = milligram, G/L = giga/liter = 10^9/L, CRP reference value: <5mg/L, leukocytes reference value: 
3.5-9.6 x 10^9/L, neutrophils reference value: 1.4-8.0 x 10^9/L, ns = not significant / p>0.05, * = p≤0.05, ** = 
p≤0.01, *** = p≤0.001, **** = p≤0.0001). Statistics: unpaired t test with Welch's correction. 
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